European Commission approves Teva inhaler; Purdue researchers develop new cancer detection method; Alnylam releases new RNAi data;

> The European Commission granted Teva Pharmaceuticals permission to market its DuoResp Spiromax multi-dose dry powder inhaler for the treatment of patients of asthma and chronic obstructive pulmonary disease. Release

> Researchers at Purdue University say they have developed a method of detecting and measuring the aggressiveness of cancer in living cells using gold nanoparticles. Article

> Alnyam released two pieces of data about the use of RNAi for the treatment of TTR-mediated amyloidosis at the International Symposium on Amyloidosis in Indianapolis. It presented the results of its Phase II open-label extension study (release) and pre-clinical data on its research in the arena. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.